APA (7th ed.) Citation

Nishihori, T., Alekshun, T., Sullivan, D., Kharfan-Dabaja, M., Raychaudhuri, J., Ochoa-Bayona, J., . . . Alsina, M. (2011). Bortezomib Followed by a Phase I Study of Bortezomib in Combination With High-Dose Melphalan as a Preparative Regimen for Hematopoietic Cell Transplants in Patients With Primary Refractory Multiple Myeloma or Plasma Cell Leukemia. Biology of Blood & Marrow Transplantation, 17(2), S200. https://doi.org/10.1016/j.bbmt.2010.12.150

Chicago Style (17th ed.) Citation

Nishihori, T., et al. "Bortezomib Followed by a Phase I Study of Bortezomib in Combination With High-Dose Melphalan as a Preparative Regimen for Hematopoietic Cell Transplants in Patients With Primary Refractory Multiple Myeloma or Plasma Cell Leukemia." Biology of Blood & Marrow Transplantation 17, no. 2 (2011): S200. https://doi.org/10.1016/j.bbmt.2010.12.150.

MLA (9th ed.) Citation

Nishihori, T., et al. "Bortezomib Followed by a Phase I Study of Bortezomib in Combination With High-Dose Melphalan as a Preparative Regimen for Hematopoietic Cell Transplants in Patients With Primary Refractory Multiple Myeloma or Plasma Cell Leukemia." Biology of Blood & Marrow Transplantation, vol. 17, no. 2, 2011, p. S200, https://doi.org/10.1016/j.bbmt.2010.12.150.